7LJ5
 
 | |
7LJA
 | |
7LJ4
 | |
1FEX
 | |
6IZC
 | |
6IZD
 | |
4N4G
 | |
8WPZ
 | |
1BJ1
 | | VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH A NEUTRALIZING ANTIBODY | | Descriptor: | Fab fragment, heavy chain, light chain, ... | | Authors: | Muller, Y.A, Christinger, H.W, De Vos, A.M. | | Deposit date: | 1998-06-30 | | Release date: | 1999-01-13 | | Last modified: | 2023-08-02 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.
Structure, 6, 1998
|
|
6IIK
 | | USP14 catalytic domain with IU1 | | Descriptor: | 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one, Ubiquitin carboxyl-terminal hydrolase 14 | | Authors: | Mei, Z.Q, Wang, Y.W, He, W, Wang, F. | | Deposit date: | 2018-10-06 | | Release date: | 2018-12-12 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (1.97 Å) | | Cite: | Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade.
Cell Res., 28, 2018
|
|
6IIM
 | | USP14 catalytic domain with IU1-206 | | Descriptor: | 1-[1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(4-hydroxypiperidin-1-yl)ethan-1-one, Ubiquitin carboxyl-terminal hydrolase 14 | | Authors: | Mei, Z.Q, Wang, J.W, Wang, F, Wang, Y.W. | | Deposit date: | 2018-10-07 | | Release date: | 2018-12-12 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.21 Å) | | Cite: | Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade.
Cell Res., 28, 2018
|
|
6IIN
 | | USP14 catalytic domain with IU1-248 | | Descriptor: | 4-{3-[(4-hydroxypiperidin-1-yl)acetyl]-2,5-dimethyl-1H-pyrrol-1-yl}benzonitrile, Ubiquitin carboxyl-terminal hydrolase 14 | | Authors: | Mei, Z.Q, Wang, J.W, Wang, F, Wang, Y.W. | | Deposit date: | 2018-10-07 | | Release date: | 2018-12-19 | | Last modified: | 2024-03-27 | | Method: | X-RAY DIFFRACTION (2.53 Å) | | Cite: | Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade.
Cell Res., 28, 2018
|
|
2M9H
 | |
7DA4
 | | Cryo-EM structure of amyloid fibril formed by human RIPK3 | | Descriptor: | Receptor-interacting serine/threonine-protein kinase 3 | | Authors: | Zhao, K, Ma, Y.Y, Sun, Y.P, Li, D, Liu, C. | | Deposit date: | 2020-10-14 | | Release date: | 2021-04-28 | | Last modified: | 2024-03-27 | | Method: | ELECTRON MICROSCOPY (4.24 Å) | | Cite: | The structure of a minimum amyloid fibril core formed by necroptosis-mediating RHIM of human RIPK3.
Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
3DJY
 | | Nonaged Form of Human Butyrylcholinesterase Inhibited by Tabun | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[beta-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, CHLORIDE ION, ... | | Authors: | Carletti, E, Nachon, F. | | Deposit date: | 2008-06-24 | | Release date: | 2008-12-02 | | Last modified: | 2021-10-20 | | Method: | X-RAY DIFFRACTION (2.1 Å) | | Cite: | Aging of Cholinesterases Phosphylated by Tabun Proceeds through O-Dealkylation.
J.Am.Chem.Soc., 130, 2008
|
|
3DKK
 | | Aged Form of Human Butyrylcholinesterase Inhibited by Tabun | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[beta-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, CHLORIDE ION, ... | | Authors: | Nachon, F, Carletti, E. | | Deposit date: | 2008-06-25 | | Release date: | 2008-12-02 | | Last modified: | 2021-10-20 | | Method: | X-RAY DIFFRACTION (2.31 Å) | | Cite: | Aging of Cholinesterases Phosphylated by Tabun Proceeds through O-Dealkylation.
J.Am.Chem.Soc., 130, 2008
|
|
4YZU
 | |
4Z0K
 | |
5JO2
 | | Crystal structure of abscisic acid-bound abscisic acid receptor PYL3 in complex with type 2C protein phosphatase HAB1 | | Descriptor: | (2Z,4E)-5-[(1S)-1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]-3-methylpenta-2,4-dienoic acid, Abscisic acid receptor PYL3, MAGNESIUM ION, ... | | Authors: | Weng, J.K, Noel, J.P. | | Deposit date: | 2016-05-01 | | Release date: | 2016-09-07 | | Last modified: | 2024-03-06 | | Method: | X-RAY DIFFRACTION (2.42 Å) | | Cite: | Co-evolution of Hormone Metabolism and Signaling Networks Expands Plant Adaptive Plasticity.
Cell, 166, 2016
|
|
5JNN
 | | Crystal structure of abscisic acid receptor PYL2 in complex with Phaseic acid. | | Descriptor: | (3S,4E)-5-[(1R,5R,8S)-8-hydroxy-1,5-dimethyl-3-oxo-6-oxabicyclo[3.2.1]octan-8-yl]-3-methylpent-4-enoic acid, Abscisic acid receptor PYL2 | | Authors: | Weng, J.K, Noel, J.P. | | Deposit date: | 2016-04-30 | | Release date: | 2016-08-17 | | Last modified: | 2024-03-06 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Co-evolution of Hormone Metabolism and Signaling Networks Expands Plant Adaptive Plasticity.
Cell, 166, 2016
|
|
5ZBH
 | | The Crystal Structure of Human Neuropeptide Y Y1 Receptor with BMS-193885 | | Descriptor: | Neuropeptide Y receptor type 1,T4 Lysozyme,Neuropeptide Y receptor type 1, dimethyl 4-{3-[({3-[4-(3-methoxyphenyl)piperidin-1-yl]propyl}carbamoyl)amino]phenyl}-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate | | Authors: | Yang, Z, Han, S, Zhao, Q, Wu, B. | | Deposit date: | 2018-02-11 | | Release date: | 2018-04-25 | | Last modified: | 2018-05-09 | | Method: | X-RAY DIFFRACTION (3 Å) | | Cite: | Structural basis of ligand binding modes at the neuropeptide Y Y1receptor
Nature, 556, 2018
|
|
5ZBQ
 | | The Crystal Structure of human neuropeptide Y Y1 receptor with UR-MK299 | | Descriptor: | Neuropeptide Y receptor type 1,T4 Lysozyme, N~2~-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-N~5~-(N'-{[2-(propanoylamino)ethyl]carbamoyl}carbamimidoyl)-D-ornithinamide | | Authors: | Yang, Z, Han, S, Zhao, Q, Wu, B. | | Deposit date: | 2018-02-12 | | Release date: | 2018-04-25 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Structural basis of ligand binding modes at the neuropeptide Y Y1receptor
Nature, 556, 2018
|
|
5FCS
 | | Diabody | | Descriptor: | Diabody, SULFATE ION | | Authors: | Mosyak, L, Root, A. | | Deposit date: | 2015-12-15 | | Release date: | 2016-12-14 | | Last modified: | 2019-11-13 | | Method: | X-RAY DIFFRACTION (2.01 Å) | | Cite: | Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.
Antibodies, 5, 2016
|
|
3JZS
 | | Human MDM2 liganded with a 12mer peptide inhibitor (pDIQ) | | Descriptor: | 1,2-ETHANEDIOL, E3 ubiquitin-protein ligase Mdm2, pDIQ peptide (12mer) | | Authors: | Schonbrunn, E, Phan, J. | | Deposit date: | 2009-09-24 | | Release date: | 2009-11-10 | | Last modified: | 2023-09-06 | | Method: | X-RAY DIFFRACTION (1.78 Å) | | Cite: | Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
J.Biol.Chem., 285, 2010
|
|
3JZO
 | | Human MDMX liganded with a 12mer peptide (pDI) | | Descriptor: | POTASSIUM ION, Protein Mdm4, pDI peptide (12mer) | | Authors: | Schonbrunn, E, Phan, J. | | Deposit date: | 2009-09-23 | | Release date: | 2009-11-10 | | Last modified: | 2023-09-06 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
J.Biol.Chem., 285, 2010
|
|
